AR and prostate cancer: One such example is AR-V7, a truncated AR isoform containing only exons 1–3 which is active even in the absence of androgens, and which is used as a biomarker for resistance to androgen-targeted therapy (ATT) in patients with prostate cancer [71,72,73].